Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 4Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1Glioma 1Glioblastoma 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × pamiparib × 1 year × Clear all
NCT03519230 2026-03-16

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

BeOne Medicines

Phase 3 Active not recruiting
224 enrolled
Gynecologic

Ovarian Neoplasms

NCT03749187 2026-03-13

PNOC017

University of California, San Francisco

Phase 1 Active not recruiting
78 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡